The retinoblastoma (RB) transcriptional corepressor 1 (RB1) is a critical tumor suppressor gene, governing diverse cellular processes implicated in cancer biology. Dysregulation or deletion in RB1 contributes to the development and progression of various cancers, making it a prime target for therapeutic intervention. RB1′s canonical function in cell cycle control and DNA repair mechanisms underscores its significance in restraining aberrant cell growth and maintaining genomic stability. Understanding the complex interplay between RB1 and cellular pathways is beneficial to fully elucidate its tumor-suppressive role across different cancer types and for therapeutic development. As a result, investigating vulnerabilities arising from RB1 deletion-associated mechanisms offers promising avenues for targeted therapy. Recently, several findings highlighted multiple methods as a promising strategy for combating tumor growth driven by RB1 loss, offering potential clinical benefits in various cancer types. This review summarizes the multifaceted role of RB1 in cancer biology and its implications for targeted therapy.
视网膜母细胞瘤（RB）转录共抑制因子1（RB1）是一个关键的肿瘤抑制基因，调控着癌症生物学中涉及的多种细胞过程。RB1的失调或缺失促进了多种癌症的发生与发展，使其成为治疗干预的重要靶点。RB1在细胞周期调控和DNA修复机制中的经典功能，突显了其在抑制异常细胞生长和维持基因组稳定性方面的重要性。理解RB1与细胞通路之间复杂的相互作用，有助于全面阐明其在不同癌症类型中的抑癌作用，并为治疗开发提供依据。因此，研究由RB1缺失相关机制产生的脆弱性，为靶向治疗提供了有前景的途径。近期多项研究指出，针对RB1缺失驱动的肿瘤生长，多种方法展现出作为有效策略的潜力，为多种癌症类型带来了潜在的临床获益。本综述总结了RB1在癌症生物学中的多方面作用及其对靶向治疗的意义。
Therapeutic Strategies for RB1-Deficient Cancers: Intersecting Gene Regulation and Targeted Therapy
肿瘤(癌症)患者之家